The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway
Open Access
- 11 May 2018
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 171 (1) , 43-52
Abstract
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Eribulin was approved for the treatment of metastatic breast cancer through the EMBRACE trial, and a subgroup analysis in this clinical trial indicated the efficacy of eribulin in patients with TNBC. However, the prognosis of patients with TNBC is still poor due to various molecular characteristics. Therefore, there is an urgent need for a more effective treatment for the management of TNBC.Keywords
Funding Information
- Oncolys Biopharma (J152001034)
This publication has 36 references indexed in Scilit:
- First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancerThe Breast, 2017
- A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer CellsMolecular Cancer Therapeutics, 2016
- Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanismsCell Death & Disease, 2016
- The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivoJournal of Hematology & Oncology, 2015
- Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studiesBreast Cancer Research and Treatment, 2014
- A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinomaInternational Journal of Oncology, 2013
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase InhibitorJournal of Clinical Oncology, 2013
- The clonal and mutational evolution spectrum of primary triple-negative breast cancersNature, 2012
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas sp.Tetrahedron Letters, 2001